Arterial hypertension is associated with serious dysfunction of the cardiovascular system and digestive system. Given the relevant role of vasoactive intestinal peptide (VIP) in the regulation of digestion process, control of blood pressure and heart rate as well as cardio- and gastro-protective character of the peptide, it appeared worthwhile to undertake the research aimed at immunohistochemical identification and evaluation of VIP-positive structures in the pylorus and heart of hypertensive rats. Up to now, this issue has not been investigated. The experimental model of hypertension in rats according to Goldblatt (two-kidney one clip model of hypertension) was used in the study. The experimental material (pylorus and heart) was collected in the sixth week of the study. VIP-containing structures were evaluated using immunohistochemical and morphometric methods. The analysis of the results showed a significant increase in the number of immunoreactive VIP structures and in the intensity of immunohistochemical staining in the stomach and in the heart of hypertensive rats. Our findings indicate that VIP is an important regulator of cardiovascular and digestive system in physiological and pathological conditions. However, to better understand the exact role of VIP in hypertension further studies need to be carried out.
MatsumuraKTsuchihashiTFujiiKIidaM. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept2003; 114: 79–86.
2.
SainsburyACooneyGJHerzogH. Hypothalamic regulation of energy homeostasis. Best Pract Res Clin Endocrinol Metab2002; 16: 623–37.
3.
VagneMKonturekSJChayvialleJA. Effect of vasoactive intestinal peptide on gastric secretion in the cat. Gastroenterology1982; 83: 250–5.
4.
FujimiyaMYamamotoHKuwaharaA. Effect of VIP and PACAP on basal release of serotonin from isolated vascularly and luminally perfused rat duodenum. Am J Physiol1998; 275: 731–9.
5.
MailmanD. Effects of vasoactive intestinal polypeptide on intestinal absorption and blood flow. J Physiol1978; 279: 121–32.
6.
OhtaTItoSOhgaA. Effects of vasoactive intestinal peptide (VIP) on contractile responses of smooth muscle in rat stomach. Br J Pharmacol1991; 102: 621–6.
7.
FujimiyaMInuiA. Peptidergic regulation of gastrointestinal motility in rodents. Peptides2000; 21: 1565–82.
RoossienABrunstingJRNijmeijerAZaagsmaJZijlstraWG. Effects of vasoactive intestinal polypeptide on heart rate in relation to vagal cardioacceleration in conscious dogs. Cardiovasc Res1997; 33: 392–9.
10.
DvorákováMC. Cardioprotective role of the VIP signaling system. Timely Top Med Cardiovasc Dis2005; 9: 33–33.
11.
DasDKKalfinRMaulikNEngelmanRM. Coordinated role of vasoactive intestinal peptide and nitric oxide in cardioprotection. Ann NY Acad Sci1998; 865: 297–308.
12.
DelgadoMMartinezCPozoDCalvoJRLecetaJGaneaDGomarizRP. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol1999; 162: 1200–5.
13.
De la FuenteMDelgadoMGomarizRP. VIP modulation of immune cell functions. Adv Neuroimmunol1996; 6: 75–91.
14.
JaniukIKasackaI. Distribution of cocaine and amphetamine regulated transcript in ureters and urinary bladder of hypertensive rats. J Biol Regul Homeost Agents2013; 27: 409–16.
15.
KasackaIArciszewskaE. Dynamics of calcitonin gene-related peptide-like cells changes in the lungs of two-kidney, one-clip rats. Eur J Histochem2012; 56: e10–e10.
16.
KasackaIPiotrowskaZLewandowskaA. Alterations of rat stomach endocrine cells under renovascular hypertension. Adv Med Sci2014; 59: 190–5.
17.
GoldblattHLynchJHanzalRFSummervilleWW. Studies on experimental hypertension I: the production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med1934; 59: 347–9.
18.
StewartPMWhorwoodCBValentinoRBurtDSheppardMCEdwardsCR. 11-beta-hydroxysteroid dehydrogenase activity and gene expression in the hypertensive Bianchi–Milan rat. J Hypertens1993; 11: 349–54.
19.
HermanGEElfontEA. The taming of immunohistochemistry: the new era of quality control. Biotech Histochem1991; 66: 194–9.
20.
BoosCJLipGY. Is hypertension an inflammatory process?Curr Pharm Des2006; 12: 1623–35.
21.
DelgadoMGaneaD. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids2013; 45: 25–39.
22.
BishopAEPolakJMBryantMGBloomSRHamiltonS. Abnormalities of vasoactive intestinal polypeptide containing nerves in Crohn’s disease. Gastroenterology1980; 79: 853–60.
23.
O'MorainCBishopAEMcGregorGPLeviAJBloomSRPolakJMPetersTJ. Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut1984; 25: 57–61.
24.
SchneiderJJehleECStarlingerMJNeunlistMMichelKHoppeSSchemannM. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn’s disease. Neurogastroenterol Motil2001; 13: 255–64.
25.
Gonzalez-ReyEDelgadoM. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology2006; 131: 1799–811.
26.
Martinez-MaldonadoM. Pathophysiology of renovascular hypertension. Hypertension1991; 17: 707–19.
27.
YeVZDugganKA. Vasoactive intestinal peptide down-regulates the intrahepatic renin-angiotensin system in the anaesthetized rat. Clin Sci (Lond)2000; 99: 201–6.
28.
WeiheEReineckeMForssmannWG. Distribution of vasoactive intestinal polypeptide-like immunoreactivity in the mammalian heart. Interrelation with neurotensin- and substance P-like immunoreactive nerves. Cell Tissue Res1984; 236: 527–40.
29.
OnuohaGNAlparEKChukwulobeluRNichollsDP. Distributions of VIP, substance P, neurokinin A and neurotensin in rat heart: an immunocytochemical study. Neuropeptides1999; 33: 19–25.
30.
ZhangRCrumpJReisinE. Regression of left ventricular hypertrophy is a key goal of hypertension management. Curr Hypertens Rep2003; 5: 301–8.
31.
SzemaAMHamidiSA. Gene deletion of VIP leads to increased mortality associated with progressive right ventricular hypertrophy. J Cardiovasc Dis2014; 2: 131–6.
32.
SzemaAMHamidiSASmithSDBenvenisteH. VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes. PLoS One2013; 8: e61449–e61449.
33.
HalleckFSchröderKHolleck-WeithmannSKossmehlPKreutzRRothermundL. Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade. Clin Exp Hypertens2015; 37: 26–32.
34.
GrönholmTChengZJPalojokiEErikssonABäcklundTVuolteenahoOFinckenbergPLaineMMervaalaETikkanenI. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. Eur J Pharmacol2005; 519: 267–76.
35.
MifsudSABurrellLMKubotaEJaworskiKCooperMEWilkinson-BerkaJL. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats. Clin Exp Hypertens2004; 26: 69–80.
36.
BellDKelsoEJArgentCCLeeGRAllenARMcDermottBJ. Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat. Cardiovasc Pathol2004; 13: 71–8.
37.
CsikósTChungOUngerT. Role of angiotensin II in hypertension-induced cardiac hypertrophy and failure. Heart Failure Rev1999; 3: 159–68.
38.
GriffinSABrownWCMacPhersonFMcGrathJCWilsonVGKorsgaardNMulvanyMJLeverAF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension1991; 17: 626–35.
39.
DickmanKMathewSBerishaHIBratutMSaidSI. Vasoactive intestinal peptide (VIP) inhibits caspase-3 activation: a basis for anti-apoptotic activity. Am J Respir Crit Care Med2000; 61: A97–A97.
40.
MisraBRMisraHP. Vasoactive intestinal peptide, a singlet oxygen quencher. J Biol Chem1990; 265: 15371–4.
41.
De FalcoMLaforgiaVFedeleVDe LucaLCottoneGDe FalcoGDe LucaA. Vasoactive intestinal peptide stimulation modulates the expression of Bcl-2 family members in the adrenal gland of the lizard Podarcis sicula. Histochem J2001; 33: 639–45.
